A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

被引：0
|
作者：
Bewersdorf, Jan Philipp
Verstovsek, Srdan
Derkach, Andriy
Masarova, Lucia
Pemmaraju, Naveen
Stein, Eytan M.
Mauro, Michael J.
Rampal, Raajit
Bose, Prithviraj
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7086
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/ Essential Thrombocythemia Myelofibrosis
    Bewersdorf, Jan Philipp
    Verstovsek, Srdan
    Derkach, Andriy
    Masarova, Lucia
    Pemmaraju, Naveen
    Stein, Eytan
    Mauro, Michael
    Rampal, Raajit K.
    Bose, Prithviraj
    BLOOD, 2022, 140 : 6844 - 6846
  • [2] A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Bewersdorf, Jan P.
    Verstovsek, Srdan
    Derkach, Andriy
    Masarova, Lucia
    Pemmaraju, Naveen
    Stein, Eytan M.
    Mauro, Michael
    Rampal, Raajit
    Bose, Prithviraj
    CANCER RESEARCH, 2023, 83 (08)
  • [3] A Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
    Bewersdorf, Jan Philipp
    Derkach, Andriy
    Masarova, Lucia
    Pemmaraju, Naveen
    Stein, Eytan M.
    Mauro, Michael
    Rampal, Raajit K.
    Bose, Prithviraj
    BLOOD, 2023, 142
  • [4] A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
    Mascarenhas, J.
    Marcellino, B. K.
    Lu, M.
    Kremyanskaya, M.
    Fabris, F.
    Sandy, L.
    Mehrotra, M.
    Houldsworth, J.
    Najfeld, V.
    El Jamal, S.
    Petersen, B.
    Moshier, E.
    Hoffman, R.
    LEUKEMIA RESEARCH, 2020, 88
  • [5] Phase II Study of Sunitinib in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
    Apostolidou, Effrosyni
    Kantarjian, Hagop
    Thomas, Deborah
    Burger, Ian
    Borthakur, Gautam
    Verstovsek, Srdan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (04): : 281 - 284
  • [6] Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis
    Masarova, Lucia
    Bose, Prithviraj
    Daver, Naval
    Pemmaraju, Naveen
    Newberry, Kate J.
    Manshouri, Taghi
    Cortes, Jorge
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    LEUKEMIA RESEARCH, 2017, 59 : 110 - 116
  • [7] RUXOLITINIB PLUS PANOBINOSTAT IN PATIENTS WITH PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: A PHASE 1B DOSE-FINDING STUDY
    Vannucchi, A. M.
    Heidel, F. H.
    Ribrag, V.
    Kiladjian, J. J.
    Passamonti, F.
    Hayat, A.
    Conneally, E.
    Kindler, T.
    Martino, B.
    Lipka, D. B.
    Acharyya, S.
    Gopalakrishna, P.
    Loechner, S.
    Mu, S.
    Harrison, C. N.
    HAEMATOLOGICA, 2014, 99 : 129 - 130
  • [8] A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia
    Mesa, R. A.
    Camoriano, J. K.
    Geyer, S. M.
    Wu, W.
    Kaufmann, S. H.
    Rivera, C. E.
    Erlichman, C.
    Wright, J.
    Pardanani, A.
    Lasho, T.
    Finke, C.
    Li, C. Y.
    Tefferi, A.
    LEUKEMIA, 2007, 21 (09) : 1964 - 1970
  • [9] A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia
    R A Mesa
    J K Camoriano
    S M Geyer
    W Wu
    S H Kaufmann
    C E Rivera
    C Erlichman
    J Wright
    A Pardanani
    T Lasho
    C Finke
    C Y Li
    A Tefferi
    Leukemia, 2007, 21 : 1964 - 1970
  • [10] Do Patients with Post-Essential Thrombocythemia and Post-Polycythemia Vera Differ from Patients with Primary Myelofibrosis?
    Masarova, Lucia
    Daver, Naval
    Pemmaraju, Naveen
    Bose, Prithviraj
    Pierce, Sherry
    Manshouri, Taghi
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    BLOOD, 2015, 126 (23)
12345